Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
Source: AJMC, April 2024
Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Changes in melanoma metastases identified using early 18F-fluorodeoxyglucose (FDG) PET/CT scans were found potentially predictive of pembrolizumab response and had a significant correlation with progression-free survival (PFS) in a study published in Clinical Cancer Research.
The study was designed to evaluate the efficacy of the noninvasive imaging biomarker for patients with cancer receiving immunotherapy and explore the biomarker’s potential to predict treatment responses at a quicker rate than standard procedures.